Invesco NASDAQ Biotech UCITS ETF Acc

Invesco NASDAQ Biotech UCITS ETF Acc is an exchange-traded fund (ETF) from Invesco, traded under the ticker SBIO (ISIN IE00BQ70R696). It lets you buy a basket of holdings in a single trade, spreading your money across them rather than one company. In plain terms it is about owning small slices of companies, so you share in their growth when they do well — and their falls when they don't, spread across its target market. It follows the NASDAQ Biotechnology Index Total Return index (passive investing): it tracks the market rather than relying on a manager, keeping running costs down, and its largest holdings include AMAZON.COM INC, APPLE INC and INTUITIVE SURGICAL INC. With about 184 holdings (the ten largest ≈ 23.9%), your money is diversified rather than concentrated in a handful of names. Geographically it leans ~88.3% United States, ~4.2% Switzerland and ~2.2% Netherlands. By industry it concentrates most in ~25.6% Technology and ~22% Health Care. It is commonly used to tilt a portfolio towards one market, usually alongside broader, more global funds rather than on its own. Its ongoing charge (TER) is 0.4% a year — about €40 a year on a €10,000 holding, taken automatically from the fund. Income such as dividends is automatically reinvested inside the fund (an accumulating share class), so returns compound without you doing anything. It tracks its index through a swap agreement rather than owning every holding (synthetic replication); it is domiciled in Ireland and UCITS-regulated, a European standard built to protect everyday investors and trades in USD. On the standard KID risk scale it is rated 5 out of 7 and its price has swung about 19.4% over the past year — a gauge of how much the value moves, not a judgement of quality. It launched in 2014, and its KID suggests a holding period of 5 years. Like any investment, it can lose value as well as gain, and what it did before does not predict what it will do next. (Fund data sourced from Invesco.)